Author: therawinformant

After a better-than-expected jobs report, stocks finished the holiday-shortened trading week on a strong note. Let's look at a few top stock trades for the first full week of July. Top Stock Trades for Tomorrow No. 1: Nio (NIO) Click to EnlargeSource: Chart courtesy of StockCharts.com The $5 to $6 zone was set to be a tough one for Nio (NYSE:NIO), which topped out in this area in the first quarter of 2020. Previously, this zone had been support for the stock, before Nio slumped badly in 2019.In any regard, electric car stocks have serious momentum right now — led by Tesla (NASDAQ:TSLA), which has amassed a market cap north of $200 billion.InvestorPlace – Stock Market News, Stock Advice & Trading TipsIn any regard, Nio shares keep pressing higher, up more than 30% so far this week. Investors undoubtedly have their eyes fixed on $10. * 7 American Manufacturing Stocks to Buy Before Recovery Let's see how the stock does with the $10 to $10.50 zone, which historically, has been resistance. If it continues as resistance, let's see that a pullback into the $6 to $7 area is met with support. Above $10.50 and the all-time highs up at $13.80 are in play. Top Stock Trades for Tomorrow No. 2: DocuSign (DOCU) Click to EnlargeSource: Chart courtesy of StockCharts.com Man, there's nothing else to say about DocuSign (NASDAQ:DOCU) other than the stock has been a complete beast.The stock never even tested its 200-day moving average during the March selloff. While shares dipped 29.9% from the February high to March low — outperforming the S&P 500 and Nasdaq during that time — the rebound has been stunning. Shares are now up more than 200% from that low.However, DocuSign stock nearly tagged $200 on Thursday and may be running out of momentum.I want to see $180 hold as support. If it doesn't, it puts uptrend support (blue line) and the 20-day moving average in play. On a larger dip, see if $150 and/or the 50-day moving average buoy the stock, whichever comes into play first. Top Stock Trades for Tomorrow No. 3: JPMorgan (JPM) Click to EnlargeSource: Chart courtesy of StockCharts.com Despite the rebound in the overall market, the bank stocks have struggled. For its part, JPMorgan (NYSE:JPM) is doing its best not to break down. But that's not exactly bullish.Shares are below all of the stock's key moving averages and are well off the June high near $115. In fact, just from that level, shares are down about 20%.On the plus side, JPM stock has carved out a nice bottom over the past few sessions. If it holds, the stock will create another higher low, giving bulls something to chew on. For them to maintain momentum though, shares need to reclaim the 50-day moving average, and preferably, the $100 to $102.50 area.If it falls below uptrend support, $82.50 is in play. Top Trades for Tomorrow No. 4: Moderna (MRNA) Click to EnlargeSource: Chart courtesy of StockCharts.com Moderna (NASDAQ:MRNA) has been a tricky stock lately, but it has traded very technically.While shares slipped about 6% in Thursday's session and lost the 50-day moving average, support near $55 is holding up. If it continues to hold, see that MRNA stock reclaims the 50-day and 20-day moving averages.Above those levels puts recent range resistance in play, up near $67.50. Pushing above that could put a move up toward $80 on the table.If $55 support breaks, shares could see $45.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 4 Top Stock Trades for Monday: NIO, DOCU, JPM, MRNA appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2BBRfsS

Jul.02 — David Bloom, global head of foreign exchange strategy at HSBC, discusses the dollar’s status as the world’s reserve currency, why the euro isn’t going up or down, and why he’s still bearish on the pound. He speaks on “Bloomberg Markets: European Open.”

from Yahoo Finance https://ift.tt/38pQS0s

Nio (NYSE:NIO) has shifted into turbo drive Thursday, but some investors might question whether shares have gas left in the tank. Let's take a look at what's happening with Nio stock to determine a risk-adjusted solution to better navigate its thrilling ride up today.Source: Sundry Photography / Shutterstock.com The market is offering investors some pre-July 4 fireworks to finish off the abbreviated workweek. The SPDR S&P Mid-Cap 400 ETF (NYSEARCA:MDY) is up 2.25% on much stronger-than-forecast monthly jobs data. The index, however, is still struggling inside a trading range more than a month in-the-making after a historic bull-run from March's corrective bottom.But that's not stopping recently crowned mid-cap Nio, whose shares continue to trade aggressively higher.InvestorPlace – Stock Market News, Stock Advice & Trading TipsNIO stock is up nearly 17% Thursday and leading its market-weighted peers to fresh relative highs. And those gains come on top of a near 100% return over the past month, which took shares from a small-cap valuation of around $3.5 billion to today's firm $8 billion mid-cap membership.So, what gives? Why is Nio continuing to race higher? Overnight, the EV outfit updated investors with its much better-than-forecast June and second quarter deliveries results. Backing today's joyride are record-breaking sales of more than 10,000 vehicles for the quarter amid the novel coronavirus. That's not all either. * 7 Utilities Stocks to Buy With Reassuring Dividends The solid performance represents boastful year-over-year growth of 190% and compares favorably to the first quarter's gain of around 170%. At the same time, Nio's cumulative deliveries on its ES8 and ES6 models reached more than 46,000 and exceeded the high end of the companies prior forecast. And the good news doesn't stop there.Nio investors may also want to thank EV peer Tesla (NASDAQ:TSLA). The outfit also offered a much stronger-than-expected deliveries update to its investors. And similarly, shares are bolting upwards of 8.50% to all-time-highs.A competitor's own good fortunes could spell doom-and-gloom under certain scenarios. But with Wall Street more or less fixated on "the good" from any and all reports and key data as economies look to put Covid-19 in the rear-view mirror, in today's market Tesla is a backseat driver for NIO stock in a good sort of way. Nio Stock Weekly Chart Source: Charts by TradingViewLooking at the price chart, shares of NIO are currently at risk of faltering in the short-term. The observation is supported by price action now in its fourth straight week outside of the weekly Bollinger Band. Stochastics have also formed a bearish crossover in overbought territory. But with Nio's recent and much-needed cash injection, still smallish capitalization and the known ability for momentum to take growth stocks like Nio strongly higher, the interpretation is not to rashly discount Nio's continued upside potential.Taking a second look at the price chart, Nio has also formed a very constructive saucer or cup-shaped corrective base over its time as publicly traded company. It's bullish. Now, with shares testing the 62% retracement level, NIO stock is inside the upper half of the pattern and well-positioned for future gains. And potentially, Nio investors should be rewarded with a breakout to all-time-highs in the coming months.Given that in the near-term Nio may be due for a rest, but there are no guarantees momentum won't continue to build. Being much more optimistic longer-term, my recommendation is investors consider the options market for assistance with a stronger risk-adjusted way to position in Nio. One favored strategy with shares near $9 is the Weeklys 15' Jan $10 / $17 bull call spread for $1.35 or better.The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post How to Approach Nio Stock At New All-Time Highs appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2NRd0HL

Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2020 contest. Matt McCall's pick for the contest is Aimmune Therapeutics (NASDAQ:AIMT).Six months ago, I introduced you to Aimmune Therapeutics (NASDAQ:AIMT) as my pick in the Best Stocks for 2020 contest. It's a leading biopharmaceutical that focuses specifically on the unmet needs of people who suffer from food allergies.The recommendation was in anticipation of the approval of its lead drug candidate. That worked out just as expected. Aimmune's treatment for peanut allergies got the green light from the U.S. Food and Drug Administration in January.InvestorPlace – Stock Market News, Stock Advice & Trading TipsThat was — and still is — a very big deal. Palforzia is the first-ever treatment for peanut allergies, and its approval sent the stock to a fresh one-year high.And then the novel coronavirus hit…The first patients were given Palforzia after the January approval, but for all intents and purposes, the rollout of this one-of-a-kind treatment came to a screeching halt. As federal and local governments implemented stay-at-home orders, allergy sufferers were forced to forgo treatments. The Coronavirus Derails AIMT StockThe healthcare system's full attention was on preparing for what some experts feared would be a flood of patients hitting hospitals. All elective surgeries and treatments came to a halt to focus on Covid-19.It did not make sense to have generally healthy allergy patients come to a doctor's office and potentially contract or unknowingly spread the virus. Peanut allergy patients have dealt with the issue for their entire lives, so apart from true emergency situations, it was not considered a critical treatment during a pandemic. * 7 Utilities Stocks to Buy With Reassuring Dividends Still, Palforzia is a much-needed breakthrough. As widespread as food allergies are, they've gotten very little attention from pharmaceutical companies. It's surprising to me that the first FDA-approved preventative treatment for peanut allergies just occurred five months ago, but it puts Palforzia in a great spot.According to Reportbuyer, Aimmune could have 67% of the peanut allergy market by 2027 — equal to $3 billion. That's a huge number for a company that has yet to generate any revenue and has a current market value of $1.1 billion.The drug is also a little more complicated than some others. Each patient receives small amounts of peanut protein through several visits to the allergist's office. They need to be closely monitored to assure there are no adverse side effects.Under normal circumstances, a few trips to the allergist to cure a potentially deadly reaction would be a godsend. However, when in the midst of a global pandemic that has killed more than 500,000 people, even something as serious as a peanut allergy may not sound so bad. In addition, when allergy sufferers stay home, they can distance themselves from potential triggers. A Return to Normal Will Boost Aimmune HigherBut countries and states are starting to reopen and life will soon return to something resembling normal. As it does, and kids go back to school while adults go back to offices and traveling, the risk of a potentially deadly peanut allergy becomes top of mind again.As of today and likely for the foreseeable future, Aimmune will have the only treatment available for peanut allergies.That's huge. And it gives Palforzia the potential to be a billion-dollar blockbuster. According to Evaluate Pharma, the drug could bring in $1.28 billion in annual sales by 2024. For a company that generated basically no sales last year, that would be a monumental achievement.Aimmune officially announced Palforzia's delay in May. At the same time, the company also said that its supply chain has not been affected and that once the stay-at-home orders are lifted, it will be ready to supply the allergists with products. The supply chain for ongoing trials is also unaffected as the company continues to push forward with testing new treatments. Keeping Our Eye on the Big PictureDue to the delay in Palforzia's rollout, revenue expectations for this year have dropped 36% from $30 million to $19 million. Next year, the treatment should be able to expand, with revenue projected to jump 4x to $130 million. That number continues to more than double annually until reaching the $1 billion milestone in 2024.By that time, earnings should be close to $6 per share — a world away from the loss of $3.97 in 2019. Some estimates are as high as $10.92 for 2024.With those numbers in mind, let's put a valuation on Aimmune. Considering the robust growth of both revenue and earnings, which is all but inevitable, it is justified to assume the stock could trade at 5x sales and 30x earnings.At five times sales of $1.28 billion, Aimmune would have a value of $6.4 billion, or $97 per share. That's a 470% gain from current prices.And if Aimmune were to trade at 30x earnings of $6 per share, it would reach $180 — or 960% above where it trades right now.Splitting the difference gets us to $138.50, a gain of 715% from the current price around $17.Of course, all of this is assuming that life gets back to normal. If I am wrong and life does not return to normal, there are far greater concerns than peanut allergies. I put the odds of this at basically zero. The reason I am so confident is that the U.S. and the world have recovered from even worse situations for thousands of years.We can defeat the Covid-19 pandemic, just like all other crises that came before it. Best Stocks: Buy AIMT Stock Right NowAimmune has received several analyst downgrades since the start of the pandemic because of Palforzia's delay. Analysts are taking a very short-term view on the stock, even though they remain bullish long term.And this gives investors a great buying opportunity.The unfortunate fact is that peanut allergies are not going anywhere. They will still exist once the pandemic passes. And as restrictions loosen up, demand for Palforzia will boom. Other investors are looking ahead to this yet, which makes Aimmune an incredibly compelling opportunity at current prices.With a market cap of $1.1 billion and projected sales of the drug expected to be in that same ballpark, this stock is flat-out cheap.Matthew McCall left Wall Street to actually help investors — by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Best Stocks for 2020: Expect Aimmune Stock to Come Back in Full Force appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/31PDwsW

On Thursday, Wedbush analyst Dan Ives raised his bull case price target for shares of Tesla to $2,000 from $1,500. While his base case was lifted from $1,000 to $1,250 (a street high), he maintains a neutral rating on the stock. The Final Round panel discusses the bullish call, and the road ahead for the electric automaker.

from Yahoo Finance https://ift.tt/38nEM81

No matter how often someone tries to frame the subject, penny stocks are inherently risky. As the name suggests, these speculative investments are typically priced below a buck (although this isn't a hard-and-fast rule). More importantly, they feature low volume and subterranean market capitalization due to their all-or-nothing nature.With the broader markets still under pressure due to the novel coronavirus, you'd assume the case for penny stocks would have died down. And in many cases, that's exactly what happened. As valuations for virtually every sector declined at the onset of the global crisis, many gamblers took their money and ran.But as major U.S. indices have trekked their way northward following their March lows, penny stocks have also attracted attention. For one thing, the down and dirty side of this investing business may run on their own fundamentals. That could be advantageous in some respects, especially as rising coronavirus cases wreak havoc on blue-chip organizations.InvestorPlace – Stock Market News, Stock Advice & Trading TipsMoreover, innovation never ceases. Right now, with both advancing technologies and their associated cost reductions, it has never been easier for startups to pioneer solutions. But to raise capital, they've got to go somewhere. Those organizations that may not attract the most attention often turn to over-the-counter markets to gain cash. * 7 Utilities Stocks to Buy With Reassuring Dividends Thus, we have the opportunity in penny stocks, but also the pitfalls. You could be sitting on the next Apple (NASDAQ:AAPL). Or you could lose your shirt like Luckin Coffee (OTCMKTS:LKNCY) speculators possibly did. If you're willing to take such extreme binary bets, here are seven companies to consider: * Blink Charging (NASDAQ:BLNK) * Champignon Brands (OTCMKTS:SHRMF) * Revive Therapeutics (OTCMKTS:RVVTF) * American Lithium (OTCMKTS:LIACF) * Fosterville South Exploration (OTCMKTS:FSXLF) * United Microelectronics (NYSE:UMC) * BIGG Digital Assets (OTCMKTS:BBKCF)As I mentioned up top, this is an extremely treacherous segment to navigate. Therefore, my recommendation is to treat this as a casino. Have fun with these seven penny stocks but do not go overboard. Penny Stocks That Could Pay Off: Blink Charging (BLNK)Source: David Tonelson/Shutterstock.com By pricing alone, Blink Charging wouldn't typically qualify in a list of "pure" penny stocks. But given that the price is under $5 at the time of this writing, I'll give Blink a pass. In addition, I want to lead with BLNK stock simply because it offers the most credible opportunity out of the speculative gambles here.After all, you've heard of electric vehicle companies like Tesla (NASDAQ:TSLA) and more recently Nikola (NASDAQ:NKLA). Clearly, the EV market is gaining ground against the mainstream combustion-engine paradigm. But the big question is, who will "fuel" a potential surge of EVs on the road? Blink answers that question with its network of charging stations.Sure, most EV owners will presumably charge their vehicles at home. However, not everyone in the U.S. has access to a garage or carport. Therefore, a fully fleshed out charging network would help EV makers expand its potential revenue pool. In turn, that should drive up BLNK stock.Plus, Blink is one of the most forward-thinking organizations. For instance, it recently announced its mobile charger platform for emergency use. This way, drivers can get that extra bit of juice to reach their homes or a nearby charging station. And that reduces anxiety for consumers who have never tried EVs, making BLNK a compelling idea. Champignon Brands (SHRMF)Source: Shutterstock Over the years, we've seen a dramatic shift in how Americans view marijuana laws. According to the Pew Research Center, two-thirds of us support full legalization. Given this dramatic turnaround, it's possible that penny stocks which are levered to alternative psychedelic medicines could rise higher in the future. One possible candidate is Champignon Brands.And no, that wasn't a typo — I did mean psychedelics, as in the kind that truly gets you high. Of course, as a controlled substance, governments everywhere would impose all kinds of strict restrictions. But the irony here is that restrictions are what would ultimately benefit SHRMF stock. As we know today, part of the collapse of the legal cannabis market was the influx of competition.With psychedelics, you've got to have the proper license to engage this sector. Immediately, that puts up a high barrier of entry that should limit competition. Further, as more people receive education about the myriad positive benefits of psychedelic medicine, investors will gradually lift SHRMF stock. * 7 Stocks to Buy That Save You Money Also, consider the present environment. Due to the social and financial stress of the coronavirus pandemic, mental health issues have accelerated. Psychedelics may offer an effective solution where other treatments have failed, thereby lifting the case for Champignon Brands. Revive Therapeutics (RVVTF)Source: Shutterstock Earlier this year, Revive Therapeutics enjoyed an explosive catalyst thanks to the coronavirus. A life sciences company, Revive announced that it was exploring the drug Bucillamine as a potential treatment for Covid-19. The move to focus on a treatment as opposed to a vaccine likely contributed to the astounding momentum of RVVTF stock.For one thing, a vaccine won't help those who already have Covid-19. More importantly, we just don't know how long it will take for a vaccine to hit the market, let alone administer it to billions across the globe. Plus, many folks have apprehensions about taking a vaccine. And don't get me started about the implications of the government forcing everyone to take it.Thus, Revive's proposal strikes a healthy balance. However, RVVTF stock is more than just a play on the coronavirus. In February of this year, Revive announced the acquisition of Psilocin Pharma, which specializes in psychedelic-based therapies. As I mentioned for Champignon, psychedelics are relevant for mental health issues that will last beyond this pandemic.However, do note the risks associated with very cheap penny stocks. With RVVTF currently priced at 14 cents, you can expect a wild ride. American Lithium (LIACF)Source: GrAl/ShutterStock.com With the slow but steady transition toward EVs, investors should take a long look at penny stocks levered toward the lithium mining industry. Yes, mining companies are well known for their incredible volatility. Further, the lithium market hasn't exactly been the bastion of stability. Nevertheless, if you're willing to absorb some risk, you may want to check out American Lithium.Focused on the production of the metal in Nevada, American Lithium offers insulation from geopolitical turbulence. Additionally, Nevada-based production may be far superior to lithium sourced in other regions, thereby bolstering the case for LIACF stock.In an email sent to me by Andrew Bowering, founder and director of American Lithium, he stated, "The Nevada Department of Geology has made a bold prediction that Nevada will one day be producing 25% of the world's lithium. It is very possible." Additionally, Bowering noted:"Chinese production challenges result from their brines being average grades of lithium but very high in Magnesium Sulfates. In addition, the production of lithium from brine requires the use of approximately 500,000 litres of water for every tonne of lithium carbonate in a typical evaporation pond operation. China has little known resources of hard rock pegmatites or claystones amenable to extraction at this time. Accordingly, they are required to seek lithium compounds and concentrates globally." * 9 Florida Stocks to Avoid as Coronavirus Rates Spike Of course, LIACT stock isn't guaranteed to rise because of Nevada's favorable platform. However, this combined with growing economic demand for lithium-based technologies makes American Lithium worth a shot, especially compared to some other penny stocks out there. Fosterville South Exploration (FSXLF)Source: Shutterstock Due to mounting fears of economic calamity along with social unrest, it's no surprise that gold-related penny stocks have shot up in demand. If you're interested in this sector, you should go with the established names, such as Newmont (NYSE:NEM) or Wheaton Precious Metals (NYSE:WPM). This way, you can enjoy the rise in precious metals while mitigating some of the volatility.However, if you're adventurous and you understand the risks associated with penny stocks, you may want to check out Fosterville South Exploration. The company has three high-grade gold projects that are centered in the Fosterville area, located in southeastern Australia. As Kirkland Lake Gold (NYSE:KL) has proven, it's a viable place to mine gold.Further, Bryan Slusarchuk, CEO of Fosterville South, explained to me via email the fundamental catalyst for FSXLF stock:"With the world having entered a phase of quantitative easing infinity, huge fiscal and monetary stimuli and low to negative interest rates, the conditions for the price of gold bullion itself are as good as I have ever seen them. Investors who have invested in the space before, know that in gold bull markets, gold equities outperform the price of the metal itself. Therefore, we are seeing a perfect storm for gold stocks."I'm biased, but I couldn't agree more. Still, like any speculative sector, I encourage due diligence before engaging. That said, the company's link to the highest-grade, low-cost gold mine is a compelling argument for FSXLF stock. United Microelectronics (UMC)Source: Shutterstock Although it's tempting to just focus on the negative headlines and react accordingly, over the long run, this pandemic will be a chapter in our history books. Logically, this means that industries of technology and innovation will continue to press forward, pushing the envelope. If you have a longer-term window, then United Microelectronics may be the right speculative investment for you.A semiconductor company specializing in integrated circuit wafers, United Microelectronics is essentially levered to a permanently strong revenue pool. That's not to say that UMC stock is guaranteed upside — far from it. Rather, digitalization is only increasing across the globe. Therefore, United Microelectronics could be a discount at these coronavirus-impacted prices. * 7 Utilities Stocks to Buy With Reassuring Dividends Also, what makes UMC stock particularly attractive is the competition. With the big dogs in the semiconductor space having jumped to ridiculous levels in recent years, United is a comparative bargain. Of course, you don't want to jump recklessly into this boat. At the same time, if you're tired of overvalued semiconductor stocks, UMC might fit the bill. BIGG Digital Assets (BBKCF)Source: Shutterstock With BIGG Digital Assets, I've saved the most intense name in this list of penny stocks for last. By intense, I'm referring to the potential for incredible riches. For one thing, BBKCF stock is priced below a dime. So, just through the law of small numbers, you could make a killing.However, do note that with penny stocks, you can also get killed. If you can't afford to lose the money you put into BIGG, I have two words for you: stay away!Yet if you're willing to accept the risk, BBKCF stock is levered to a compelling business that will only grow in pertinence. A blockchain-based organization, BIGG Digital Assets owns and operates cryptocurrency-related companies that support a regulated and compliant ecosystem. In other words, BIGG is looking to mainstream blockchain-powered solutions and platforms.In my opinion, I believe BIGG's QLUE business offers the most potential. An acronym that stands for "Qualitative Law Enforcement Unified Edge," QLUE assists law enforcement agencies in tracking down crypto-related crimes. While decentralization offers consumer-level benefits, it also opens the door to nefarious actors.With QLUE, governments can potentially crack down on financial cybercrimes. As interest picks up in the crypto space, such enforcement measures will only increase in demand.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he is long NKLA, SHRMF, and gold bullion.With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 7 Risky Penny Stocks (That Could Really Pay Off) appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/3e5e7hL

Microsoft (NASDAQ:MSFT) stock is up almost 30% this year and nearly twice as much off its March lows, but even with a $1.55 trillion market capitalization, Microsoft can still deliver for investors.Source: NYCStock / Shutterstock.com The software giant is jostling with rivals Apple (NASDAQ:AAPL) and Amazon (NASDAQ:AMZN) to be the first company to enter the $2 trillion club. While that illustrious distinction is far away for all three, Microsoft still offers ample appreciation potential.Yes, investors buying Microsoft today will be paying a forward earnings multiple of 31.25 and a sales multiple of 11. Those are growth stock multiples because, well, Microsoft is a growth stock. It's the largest component in the S&P 500 Growth Index at a weight of 10%.InvestorPlace – Stock Market News, Stock Advice & Trading Tips * 7 Utilities Stocks to Buy With Reassuring DividendsThat status shouldn't be off-putting to investors. They should embrace it because over the past decade, growth stocks handsomely outperformed their value rivals.Researchers at Columbia University's business school suggest that many investors are seduced by low price-book ratios, thinking they're getting a good deal, when in reality growth stocks can be less risky than value names. Near-Term Microsoft MomentumA large part of the thesis for Microsoft revolves around the company's burgeoning Azure cloud business, the second-largest cloud computing outfit beyond Amazon's Amazon Web Services (AWS). Within Azure is Teams, Microsoft's competitor to Slack (NYSE:WORK) and Zoom Video (NASDAQ:ZM).That means Microsoft is a credible novel coronavirus idea and/or a play on the seismic shifts happening in the way people work. The economy started reopening in May, but even now many parts of the U.S. are awash in new cases of Covid-19. Many folks haven't returned to their offices and some that have could easily be sent back to remote status in the name of safety.Even if a vaccine for the vaccine emerges tomorrow, how and where folks work is dramatically altered and that's to the benefit of companies with cloud computing footprints. Remember, Microsoft CEO Satya Nadella recently said, "We've seen two years' worth of digital transformation in two months."Adding to the Azure case is that while cloud computing itself is classified as a disruptive technology, it also serves as a foundation for other technologies that are shifting the corporate and consumer landscapes.Data confirms that Azure is making significant inroads against rival AWS. Earlier this year, a Goldman Sachs survey of 100 information technology executives at large companies revealed 56% use Azure while 48 percent deploy AWS. The Bottom Line for MSFT StockThere are more than just other factors that bode well for Microsoft over the back half of 2020, but I'm going to mention a pair here.First, through Azure Office 365 and Dynamics 365, among other offers, Microsoft transitioned to a subscription model perhaps more effectively than any large IT company in recent memory. The benefit there is two-fold: accelerating and predictable revenue.Second, Microsoft is a legitimate gaming company and the latest version of the Xbox is coming just in time for the holiday shopping season. It's widely known that this is the year of the hardware upgrade cycle, but Microsoft could potentially surprise gamers and investors with unexpected offerings. Plus gaming, like work from home, is one of the few non-healthcare investment strategies benefiting in earnest from the pandemic.Wrapping it all up, Microsoft stock is up quite a bit, but it has the management team and the catalysts to deliver more upside for shareholders.Todd Shriber has been an InvestorPlace contributor since 2014. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Surging Microsoft Still Checks Plenty of Positive Boxes appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2C8r50w

Robert Hockett, Edward Cornell Professor of Law at Cornell Law School, highlights the significance of Reconstruction for the U.S. and why 2020 is the right time to re-introduce it.

from Yahoo Finance https://ift.tt/2YVHDBV